Assessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry

Figures & data

Table 1. Number of prescriptions within PTSD-related drug classes, with changes to prescriptions following commencement of CBMP treatment displayed.

Medication	Total	No Change	Stopped Taking	Reduced Dose	Increased Dose	New Medication
Antidepressants, n (%)	124	114 (91.94%)	10 (8.06%)	1 (0.81%)	3 (2.42%)	4 (3.23%)
Benzodiazepines, n (%)	28	27 (96.43%)	1 (3.57%)	0 (0.00%)	0 (0.00%)	1 (3.57%)
Insomnia-related, n (%)	14	14 (100.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)

Table 2. Change in PROMs from baseline to follow-up at 1-, 3-, and 6-months. Reported as median (IQR) *p < 0.050, **p < 0.010, ***p < 0.001.

PROM	Followup month	n	Baseline Score median (IQR)	Follow-up Score median (IQR)	p-value	T-test statistic	Z-score	Effect size (r)
IES-R Avoidance	1-month	127	19.00 (14.00–23.00)	16.00 (11.00–20.00)	<0.001***	5386.00	−4.82	−0.30
	3-months	88	18.00 (14.00–22.00)	11.50 (6.25–17.00)	<0.001***	2976.00	−5.60	−0.42
	6-months	45	18.00 (13.50–21.00)	12.00 (7.00–16.50)	<0.001***	662.00	−3.80	−0.40
IES-R Intrusions	1-month	127	23.00 (18.00–27.00)	15.00 (10.00–22.00)	<0.001***	6111.00	−6.74	−0.42
	3-months	88	22.50 (17.00–26.75)	13.00 (6.25–19.00)	<0.001***	3219.50	−6.40	−0.48
	6-months	45	19.00 (12.00–23.50)	11.00 (5.00–17.00)	<0.001***	845.00	−4.49	−0.47
IES-R Hyperarousal	1-month	127	18.00 (14.00–21.00)	12.00 (8.00–16.00)	<0.001***	6422.00	−7.07	−0.44
	3-months	88	18.00 (12.00–20.00)	10.00 (5.25–15.00)	<0.001***	3200.50	−6.62	−0.50
	6-months	45	16.00 (9.50–19.00)	8.00 (5.00–14.00)	<0.001***	778.00	−4.10	−0.43
IES-R Total Score	1-month	127	59.00 (49.00–68.00)	44.00 (30.00–57.00)	<0.001***	6775.50	−6.76	−0.42
	3-months	88	58.00 (43.50–65.00)	34.00 (18.50–50.00)	<0.001***	3317.00	−6.53	−0.49
	6-months	45	56.00 (37.00–62.50)	32.00 (20.50–48.50)	<0.001***	914.50	−4.48	−0.47
EQ-5D-5L Mobility	1-month	133	1.00 (1.00–3.00)	1.00 (1.00–2.00)	0.300	507.50	−1.04	−0.06
	3-months	94	1.00 (1.00–3.00)	1.00 (1.00–2.00)	0.009**	275.00	−2.61	−0.19
	6-months	51	1.00 (1.00–2.00)	1.00 (1.00–2.00)	0.134	75.00	−1.50	−0.15
EQ-5D-5L Usual Activities	1-month	133	3.00 (2.00–4.00)	2.00 (1.50–3.00)	<0.001***	2802.00	−5.03	−0.31
	3-months	94	3.00 (2.00–3.00)	2.00 (1.00–3.00)	<0.001***	1695.00	−4.91	−0.36
	6-months	50	3.00 (1.00–3.00)	2.00 (1.00–2.25)	0.012*	369.00	−2.52	−0.25
EQ-5D-5L Self Care	1-month	133	2.00 (1.00–3.00)	2.00 (1.00–2.00)	0.044*	892.00	−2.02	−0.12
	3-months	94	2.00 (1.00–3.00)	1.00 (1.00–2.00)	0.017*	429.50	−2.39	−0.17
	6-months	50	1.00 (1.00–2.00)	1.00 (1.00–2.00)	0.334	50.50	−0.97	−0.10
EQ-5D-5L Pain and Discomfort	1-month	133	3.00 (1.00–3.00)	2.00 (1.00–3.00)	<0.001***	1594.00	−3.40	−0.21
	3-months	94	2.00 (1.00–3.00)	2.00 (1.00–3.00)	<0.001***	933.00	−3.80	−0.28
	6-months	50	2.00 (1.00–3.00)	2.00 (1.00–3.00)	0.584	168.50	−0.55	−0.05
EQ-5D-5L Anxiety and Depression	1-month	133	4.00 (3.00–4.00)	3.00 (2.00–4.00)	<0.001***	3433.00	−6.05	−0.37
	3-months	94	3.00 (3.00–4.00)	2.50 (2.00–3.00)	<0.001***	1841.00	−5.17	−0.38
	6-months	50	3.00 (2.00–4.00)	3.00 (2.00–3.00)	0.003**	464.00	−2.93	−0.29
EQ-5D-5L Index Value	1-month	133	0.42 (0.21–0.66)	0.59 (0.41–0.74)	<0.001***	6014.00	−6.01	−0.37
	3-months	94	0.51 (0.25–0.72)	0.71 (0.51–0.77)	<0.001***	3298.00	−5.58	−0.41
	6-months	50	0.59 (0.35–0.81)	0.69 (0.54–0.77)	0.024*	807.50	−2.25	−0.23
GAD7	1-month	133	15.00 (11.50–19.00)	8.00 (5.00–13.50)	<0.001***	6773.50	−7.73	−0.47
	3-months	94	15.00 (8.75–18.00)	7.00 (4.00–11.00)	<0.001***	3364.50	−6.74	−0.49
	6-months	50	13.50 (6.00–18.00)	7.00 (4.00–9.25)	<0.001***	965.50	−4.25	−0.43
SQS	1-month	133	3.00 (2.00–5.00)	6.00 (3.00–7.00)	<0.001***	5720.50	−6.69	−0.41
	3-months	94	3.50 (2.00–5.00)	5.00 (4.00–7.25)	<0.001***	2561.00	−5.10	−0.37
	6-months	50	4.00 (2.75–6.00)	6.00 (4.00–7.00)	0.037*	730.50	−2.09	−0.21

Table 3. Incidence of all adverse events (AE) reported by patients (n = 33), classed by severity groups of mild, moderate, severe, and life-threatening/disabling (LT/D). Total values are reported as incidence n (%). Average duration of each AE is reported as median (IQR).

Adverse Events	Mild	Moderate	Severe	LT/D	Total n(%)	Median Duration, days
Abdominal pain (upper)	-	1	-	-	1 (0.62%)	5.00
Amnesia	3	2	-	-	5 (3.09%)	7.00 (5.00–11.00)
Anorexia	1	4	1	-	6 (3.70%)	7.00 (4.50–90.00)
Anxiety	2	1	2	-	5 (3.09%)	7.00 (1.00–42.00)
Arthritis	-	-	1	-	1 (0.62%)	7.00
Ataxia	3	1	-	-	4 (2.47%)	4.50 (2.00–7.00)
Blurred vision	3	1	-	-	4 (2.47%)	2.00 (1.25–5.75)
Cognitive Disturbance	3	2	2	-	7 (4.32%)	7.00 (7.00–14.00)
Confusion	3	3	1	-	7 (4.32%)	7.00 (1.00–7.00)
Concentration impairment	8	4	2	-	14 (8.64%)	6.00 (3.00–7.00)
Constipation	2	-	-	-	2 (1.23%)	2.50
Delirium	2	1	-	-	3 (1.85%)	7.00
Decreased Weight	6	2	-	-	8 (4.94%)	9.00 (3.25–49.75)
Diarrhea	1	-	-	-	1 (0.62%)	2.00
Distorted thoughts	-	1	-	-	1 (0.62%)	1.00
Dizziness	2	4	2	-	8 (4.94%)	2.00 (1.00–7.00)
Dry mouth	14	-	-	-	14 (8.64%)	7.00 (3.75–15.50)
Dysgeusia	2	-	1	-	3 (1.85%)	30.00
Dyspepsia	4	-	-	-	4 (2.47%)	1.00 (1.00–5.50)
Fatigue	8	10	2	-	20 (12.35%)	5.00 (3.00–7.00)
Headache	8	6	1	-	15 (9.26%)	4.00 (1.00–7.00)
Insomnia	3	10	7	-	20 (12.35%)	6.00 (4.25–10.00)
Intrusive thoughts	1	-	-	-	1 (0.62%)	0.00
Irritability	-	2	-	-	2 (1.23%)	3.50
Lethargy	8	5	-	-	13 (8.02%)	7.00 (4.00–9.50)
Muscular Weakness	3	1	1	-	5 (3.09%)	2.00 (1.50–5.50)
Nausea	3	5	1	-	9 (5.56%)	6.00 (2.50–8.50)
Nightmares	-	-	2	-	2 (1.23%)	5.00
Paranoia	-	-	1	-	1 (0.62%)	75.00
Pharyngitis	-	4	-	-	4 (2.47%)	10.50 (2.00–49.75)
Pyrexia	1	-	-	-	1 (0.62%)	1.00
Rash	1	1	-	-	2 (1.23%)	17.50
Respiratory Infection	-	1	-	-	1 (0.62%)	7.00
Somnolence	-	12	1	-	13 (8.02%)	4.00 (3.50–7.00)
Spasticity	2	-	-	-	2 (1.23%)	2.50
Tremor	2	2	-	-	4 (2.47%)	5.50 (3.25–16.00)
Vertigo	1	3	1	-	5 (3.09%)	2.00 (1.00–33.50)
Vomiting	-	1	1	-	2 (1.23%)	3.50
Total	100 (61.73%)	90 (55.56%)	30 (18.52%)	0 (0.00%)	220 (135.80%)

Data availability statement

Data that support the findings of this study are available from the UK Medical Cannabis Registry (https://ukmedicalcannabisregistry.com/). Restrictions apply to the availability of these data. Data specifications and applications are available from the corresponding author.